Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy
2007-005951-40Phase 3Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of raltegravir in human immunodeficiency virus infection (HIV) and Seroconversion Syndrome, sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoints: First-phase decay rate of plasma HIV-1 RNA, Second-phase decay rate of plasma HIV-1 RNA and 2 more. Started Jan 2008; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)Seroconversion Syndrome
Beyond the preview
Go deeper on 2007-005951-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005951-40.